Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07222488RecruitingPhase 1/Phase 2
Study of MK-3120 for bladder cancer
This trial tests a new drug, MK-3120, for people with a specific type of bladder cancer that hasn't spread into the muscle. It is for patients who either haven't had BCG treatment before or have had BCG treatment and their cancer came back more than 12 months but within 2 years after the last dose.
Bakersfield, CaliforniaAges 18 years+ - NCT07419295RecruitingPhase 3
Testing a new drug for advanced bladder cancer
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06694480RecruitingPhase 1
Study of FID-022 for advanced solid tumors
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
Duarte, CaliforniaAges 18 years+ - NCT07545265RecruitingPhase 1/Phase 2
SKB565 injection for advanced solid cancers
This study tests SKB565, a new injectable cancer treatment, in people with advanced solid tumors (cancer that has spread or hasn't responded to standard treatments). The trial aims to find the right dose and learn how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07070232RecruitingPhase 1/Phase 2
Testing a new drug BNT326 for advanced cancers
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT06795412RecruitingPhase 1/Phase 2
PYX-201 plus pembrolizumab for advanced solid tumors
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
San Diego, CaliforniaAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT05981703RecruitingPhase 1
Study of BGB-26808 alone or with tislelizumab for advanced solid tumors
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT07371234RecruitingPhase 2
Low-dose radiation and immunotherapy before surgery for head and neck cancer
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
GuangdongAges 18–75 - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Sarasota, FloridaAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Birmingham, AlabamaAges 18 years+ - NCT06992258RecruitingPhase 2
Comparing two drug combinations for advanced colorectal cancer
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
New Haven, ConnecticutAges 18 years+ - NCT07490301RecruitingPhase 2/Phase 3
Study of a new drug combo for first-line metastatic pancreatic cancer
This trial tests a new targeted drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for people with advanced pancreatic cancer that has spread. The goal is to see if this combination works better than current treatments.
Chicago, IllinoisAges 18 years+ - NCT07700160RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07310784RecruitingPhase 2
Testing LM103 for advanced melanoma
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07111546RecruitingPhase 2
A study of LBL-024 combination for advanced solid tumors
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
Hefei, AnhuiAges 18–75 - NCT07293351RecruitingPhase 1/Phase 2
Pumitamig alone or with other drugs for advanced kidney cancer
This study tests a new drug called pumitamig, given alone or with other treatments, for people with advanced kidney cancer that has spread or cannot be removed. It aims to see if the drug is safe and if it helps shrink tumors.
Palo Alto, CaliforniaAges 18 years+ - NCT07792720Recruiting
Platelet-rich fibrin and hyaluronic acid for dental implant healing
This study tests whether adding platelet-rich fibrin (a substance made from your blood that helps healing) and hyaluronic acid (a natural joint and tissue lubricant) to dental implants improves healing. If you need a dental implant in your lower back teeth and are generally healthy, this might help you heal faster and more comfortably.
Sanaa, Sana'aAges 18–65 - NCT07554339RecruitingPhase 3
Calderasib and Durvalumab for Advanced Lung Cancer After Chemotherapy
This trial tests a combination of two drugs—calderasib (a targeted therapy) and durvalumab (an immunotherapy)—for people with a specific type of advanced lung cancer that has a KRAS G12C mutation. The goal is to prevent the cancer from coming back after standard chemotherapy and radiation treatment.
Lincoln, NebraskaAges 18 years+ - NCT07190248RecruitingPhase 3
Calderasib plus other treatments for advanced non-small cell lung cancer
This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.
Birmingham, AlabamaAges 18 years+ - NCT04485286RecruitingTeam says not enrollingPhase 2
PET scan tracer to find lung or pancreas radiation injury
This Phase 2 study tests a special PET scan tracer to help doctors spot tissue damage after radiation treatment in people with certain lung or pancreatic cancers. The goal is to improve detection and planning around chemoradiation and surgery.
Boston, MassachusettsAges 18–80 - NCT06938282RecruitingPhase 2
Study of HRS-4642 with immunotherapy and chemo for pancreatic cancer
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07617727RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
Fuzhou, FujianAges 18–75 - NCT06337695RecruitingPhase 2/Phase 3
Preventing immunotherapy-related diarrhea in advanced cancer
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
Calgary, AlbertaAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,211 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.